Navigation Links
Ethicon Endo-Surgery to Acquire SurgRx
Date:8/11/2008

- Acquisition will bring together two complementary technologies to extend reach into multiple key surgical activities, offering improved options for

physicians and patients worldwide -

CINCINNATI, Aug. 11 /PRNewswire/ -- Ethicon Endo-Surgery announced today that it has entered into a definitive agreement to acquire SurgRx, a privately held developer of the advanced bipolar tissue sealing system used in the EnSeal(R) family of devices. The acquisition will provide Ethicon Endo-Surgery with a new energy platform, which complements its HARMONIC(R) line of ultrasonic medical devices that have been used to perform open and laparoscopic procedures worldwide.

Terms of the agreement were not disclosed. The transaction is subject to customary clearances, including the Hart-Scott-Rodino Antitrust Improvements Act and similar regulations in other countries.

"Ethicon Endo-Surgery and SurgRx share a commitment to innovation for the surgeons and patients who depend on our products," said Karen Licitra, Company Group Chairman and Worldwide Franchise Chairman, Ethicon Endo-Surgery. "Together, the combination of HARMONIC(R) and EnSeal(R) technologies will position us to better address many different procedure needs."

"The acquisition has the potential to expand the global availability of the EnSeal(R) product line," said Rodney Perkins M.D., Chairman, Board of Directors, SurgRx. Dave Clapper, President & CEO, SurgRx added, "We are looking forward to joining forces with Ethicon Endo-Surgery to offer these complementary technologies to even more patients worldwide." SurgRx was founded in 2002 and is located in Redwood City, Calif. The EnSeal(R) family of devices combines high compression and controlled energy delivery to quickly create strong vessel seals. The EnSeal(R) device, cleared by the FDA in 2003, is capable of sealing vessels up to 7mm in diameter.

About Ethicon Endo-Surgery

Ethicon Endo-Surgery, Inc., a Johnson & Johnson company, develops and markets advanced medical devices for minimally invasive and open surgical procedures, focusing on procedure-enabling devices for the interventional diagnosis and treatment of conditions in general and bariatric surgery, as well as gastrointestinal health, gynecology and surgical oncology. More information can be found at http://www.ethiconendo.com.

HARMONIC is a trademark of Ethicon Endo-Surgery, Inc.

EnSeal is a trademark of SurgRx, Inc.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Ethicon Endo-Surgery's expectations and projections. Risks and uncertainties include the satisfaction of closing conditions for the acquisition, including receipt of regulatory approvals for the transaction, and the possibility that the transaction will not be completed; general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2007. Copies of this Form 10-K, as well as subsequent filings, are available online at http://www.sec.gov, http://www.jnj.com or on request from Johnson & Johnson. Ethicon Endo-Surgery does not undertake to update any forward-looking statements as a result of new information or future events or developments.)


'/>"/>
SOURCE Ethicon Endo-Surgery, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ETHICON, INC. Announces Revised Label For REGRANEX(R) (becaplermin) Gel 0.01%
2. Duff & Phelps Acquires Lumin Expert Group To Build Global Intellectual Property Practice
3. Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
4. Bioheart, Inc., Announces Letter of Intent to Acquire MEDICALGORITHMICS, Ltd.
5. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
6. Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash
7. BioEnergy International, LLC Acquires Assets of OmniGene Bioproducts, Inc.
8. Teva to Acquire Barr
9. MacroGenics Acquires Raven Biotechnologies
10. FDA Advisory Committee Provides Opinion of DORIBAX(TM) for the Treatment of Hospital-Acquired Pneumonia
11. Video: New, Advanced Therapy Program Helps People Who Stutter Acquire Fluent Speech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... Mass. , Nov. 30, 2016   Merck ... that it has entered into a set of agreements ... services for Merck,s collection of genetic reagents such as ... with Evotec,s screening expertise offers an accelerated pathway to ... discovery starts with the identification of new targets, a ...
(Date:11/30/2016)... ... November 30, 2016 , ... Energetiq Technology, a world leader ... generation, ultra-bright, Laser-Driven Light Source, the EQ-77, at the MRS Fall Exhibit 2016. ... offers higher radiance and irradiance from a truly broadband white light source. The ...
(Date:11/30/2016)... ... November 30, 2016 , ... On 28 November 2016, the International Union ... nihonium (Nh), moscovium (Mc), tennessine (Ts), and oganesson (Og), respectively for element 113, ... earlier proposed by the discoverers have been approved by the IUPAC Bureau. The IUPAC ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... of precision treatments for neurodegenerative diseases, today announced that all five of its ... 3, 2016) blocked propagation of toxic, prion-like forms of Amyloid beta (Aß) in ...
Breaking Biology Technology:
(Date:11/15/2016)... 15, 2016  Synthetic Biologics, Inc. (NYSE MKT: ... on the gut microbiome, today announced the pricing ... of its common stock and warrants to purchase ... price to the public of $1.00 per share ... from the offering, excluding the proceeds, if any ...
(Date:6/27/2016)... 2016 Research and Markets has announced the ... report to their offering. The ... to grow at a CAGR of 12.28% during the period ... an in-depth market analysis with inputs from industry experts. The report ... years. The report also includes a discussion of the key vendors ...
(Date:6/21/2016)... Columbia , June 21, 2016 ... to the new role of principal product architect ... named the director of customer development. Both will ... chief technical officer. The moves reflect NuData,s strategic ... in response to high customer demand and customer ...
Breaking Biology News(10 mins):